CBIO - NASDAQ
Crescent Biopharma, Inc.
$18.45
+8.5%Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.
At a Glance
Live Snapshotcbio
Cash at End of Period
Last Annual Value
213.30M
3-Year CAGR
65%
5-Year CAGR
9%
10-Year CAGR
16%
Crescent Biopharma, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Crescent Biopharma, Inc. NASDAQ:CBIO | 213.30M | 72.2% | 18.8% | 18.2% | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 54.22M | -6.9% | -15.0% | N/A | |
 Anixa Biosciences, Inc. NASDAQ:ANIX | 1.24M | 10.8% | -46.8% | -6.7% | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 17.47M | -6.9% | 7.9% | 2.3% | |
 Greenwich LifeSciences, Inc. NASDAQ:GLSI | 6.18M | -4.0% | -25.7% | N/A | |
 PepGen Inc. NASDAQ:PEPG | 62.06M | -9.0% | -14.3% | N/A | |
 Tevogen Bio Holdings Inc. NASDAQ:TVGN | 1.28M | 6.8% | -29.0% | N/A | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 14.08M | -9.9% | 4.2% | 9.4% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 20.95M | -23.5% | -35.0% | -0.5% | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 78.05M | -15.6% | -0.3% | N/A | |
 Heron Therapeutics, Inc. NASDAQ:HRTX | 28.65M | -0.0% | -20.6% | 7.9% |
Crescent Biopharma, Inc. Fair Value Envelope
Related Guides
Continue your CBIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.